<DOC>
	<DOCNO>NCT02980341</DOCNO>
	<brief_summary>This open-label , three-part , non-randomized , multiple-dose study evaluate safety , tolerability , efficacy U3-1402 patient HER3-positive metastatic breast cancer . HER3 unique member human epidermal growth factor receptor , define certain type cancer . The number patient treatment cycle fix study . Subjects continue derive clinical benefit study treatment absence withdrawal consent , progressive disease ( PD ) , unacceptable toxicity may continue study treatment end trial .</brief_summary>
	<brief_title>Phase I/II Study U3-1402 Subjects With Human Epidermal Growth Factor Receptor 3 ( HER3 ) Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Has pathologically document advanced/unresectable metastatic breast cancer . 2 . Eastern Cooperative Oncology Group performance status 0 1 . 3 . Documented HER3positive disease measure immunohistochemistry ( IHC ) ( IHC 2+ 3+ ) . 4 . Has treat standard treatment , standard treatment available . 5 . Has Eastern Cooperative Oncology Group Performance Status 01 . 6 . Has Left Ventricular Ejection Fraction â‰¥ 50 % . 7 . Has measurable disease base Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Additional Inclusion Criteria Dose Finding Part Phase 2 Part 1 . Has receive 6 few prior chemotherapy regimen include anthracyclines taxanes . 1 . Prior treatment HER3 antibody . 2 . Prior treatment antibodydrug conjugate ( ADC ) consist exatecan derivative topoisomerase I inhibitor ( eg , DS8201 ) . 3 . Has medical history symptomatic congestive heart failure ( New York Heart Association class IIIV ) serious cardiac arrhythmia require treatment . 4 . Has medical history myocardial infarction unstable angina . 5 . Has correct QT prolongation &gt; 450 millisecond ( m ) males &gt; 470 m female . 6 . Has medical history clinically significant lung disease ( eg , interstitial pneumonia , pneumonitis , pulmonary fibrosis , severe radiation pneumonitis ) suspect disease image screen period . 7 . Has cataract , glaucoma , increase intraocular pressure baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Oncology</keyword>
	<keyword>HER3</keyword>
	<keyword>Antibody drug conjugate</keyword>
	<keyword>Developmental Phase I/II</keyword>
</DOC>